Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.

Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.